https://www.selleckchem.com/pr....oducts/z-vad(oh)-fmk
No significant difference in risks of stroke or TIMI non-CABG major bleeding (HR 1.24; 95% CI 0.90-1.73; P = .191; I2 = 0%) was observed between potent oral P2Y12 inhibitors and clopidogrel. CONCLUSION Potent oral P2Y12 inhibitors, especially ticagrelor, decrease the risk of ischemic events in MMACS patients as compared with clopidogrel, without significantly increasing major bleeding.Genetic factors play an important role in determining the susceptibility to ischemic stroke. Herein, we examined the association of an aldehyde dehy
Like
Comment
Share
